Patents Assigned to Santaris Pharama A/S
  • Patent number: 8357670
    Abstract: Oligonucleotides directed against the hypoxia-inducible factor-1? (HIF-1?) gene are provided for modulating the expression of HIF-1?. The compositions comprise oligonucleotides, particularly antisense oligonucleotides, targeted to nucleic acids encoding the HIF-1?. Methods of using these compounds for modulation of HIF-1? expression and for the treatment of diseases associated with the hypoxia-inducible factor-1? are provided. Examples of diseases are cancer and pre-eclampsia. The oligonucleotides may be composed of deoxyribonucleosides, a nucleic acid analogue, or Locked Nucleic Acid (LNA) or a combination thereof.
    Type: Grant
    Filed: May 22, 2012
    Date of Patent: January 22, 2013
    Assignees: Enzon Pharmaceuticals, Inc., Santaris Pharama A/S
    Inventors: Charlotte Albaek Thrue, Anja Molhart Hog, Paul E. G. Kristjansen